Compare TMCI & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | SEER |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 97.3M |
| IPO Year | 2021 | 2020 |
| Metric | TMCI | SEER |
|---|---|---|
| Price | $4.21 | $2.09 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.77 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $212,690,000.00 | $16,578,000.00 |
| Revenue This Year | N/A | $2.14 |
| Revenue Next Year | $8.18 | $25.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.59 | ★ 16.99 |
| 52 Week Low | $1.17 | $1.55 |
| 52 Week High | $7.78 | $2.41 |
| Indicator | TMCI | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 59.16 |
| Support Level | $3.84 | $1.70 |
| Resistance Level | $4.62 | $2.09 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 33.33 | 67.73 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.